A substantial advancement in glucose care is emerging with the approval of tirzepatide at a dosage of 45mg. This new formulation builds upon the existing success of tirzepatide, a dual GIP and GLP-1 receptor, and https://tayavrkk287198.ivasdesign.com/62012769/revolutionary-introduction-tirzepatide-strength-for-diabetes-control